Where Human Insight Meets Artificial Intelligence
One company that uses AI where it truly moves the needle is Evotec, a global drug discovery and development partner headquartered in the heart of Europe, in Hamburg. The company’s integration of computation, biology, and experimental design is driving drug discovery workflows where algorithms and seasoned drug developers push each other forward.
Evotec offers fully end to end drug discovery and development capabilities – from target identification and validation to hit identification, lead optimization, IND preparation, early clinical development, and Phase I-III support. Its platforms span highthroughput screening, multiomics technologies, and advanced in silico design.
The company has a strong track record of progressing drugs to the clinic and the market, and strong technological capabilities. Leaders at Evotec argue that the real frontier of the business is not algorithms alone, but the way their experienced drug developers weave AI into their processes.
Related Stories
AI News
What The Tech: AI Is No Longer Just Answering Questions
41 minutes ago
AI News
Opinion: Artificial intelligence needs oversight before it runs amok
41 minutes ago
AI News
College holds community ‘roundtable discussion and listening session’ on artificial intelligence
41 minutes ago
AI News
Vilnius-based Holo raises €5M to bring AI
1 hour ago
AI News
Freshfields partners explore carve
2 hours ago
AI News
Artificial intelligence grows to 'risk front and centre' for Canada's banking regulator
2 hours ago
AI News
Profitable French accounting company Dougs raises €50 million to accelerate AI automation
3 hours ago
AI News
Exclusive | US, China race to shape AI agenda ahead of Xi
4 hours ago